Agreement: I Agree Body: Dear Editor Siebert and Tibau argue that better documentation of dissent within licensing committees will clarify evidence uncertainty [1]. This proposal is valuable but incomplete. Recording dissent is necessary, but it is not sufficient. Transparency without enforcement mechanisms risks becoming performative. The core problem is not the absence of documented disagreement, but the absence of consequences for ignoring it. Empirical evidence from clinical trial reporting